米氮平和丁螺环酮治疗广泛性焦虑症的对照研究

目的：比较米氮平与丁螺环酮治疗广泛性焦虑症的疗效及不良反应。方法：将符合CCMD—Ⅲ诊断标准的64例广泛性焦虑症患者随机分为两组，分别服米氮平或丁螺环酮治疗6周，于疗前和疗后第6周末进行汉密尔顿焦虑量表（HAMA）、焦虑自评量表（SAS）、临床疗效总评（CGI—SI）和副反应量表（TESS）评定疗效和不良反应。结果：米氮平和丁螺环酮疗效相仿，但躯体焦虑因子分有显著性差异。两组不良反应均轻而易耐受。结论：米氮平是治疗广泛性焦虑症的安全有效药物，更适用于伴重性抑郁的广泛性焦虑症。

A comparative study between mirtazapine and buspirone in the treatment of generalized anxiety disorder

Objective:To evaluate the efficacy and side effects of mirtazapine and buspirone in the treatment of generalized anxiety disorder. Methods:Sixty-four patients with generalized anxiety disorder met the criteria of CCMD-III were randomly assigned to receive mirtazapine (n=34) or buspirone (n=30). HAMA, SAS, CGI-SI and TESS were adopted to evaluate the efficacy and side effects before and after six weeks of the treatment. Results: The efficacy of mirtazapine and buspirone had no significant difference, but mirtazapine was better than buspirone in the treatment of physical anxiety patient. They had slighter side effects. Conclusions:Mirtazapine is a safe and effective drug in the treatment of generalized anxiety disorder, suiting for generalized anxiety disorder with major depression.